会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • INHIBITION OF INFLAMATION USING ALPHA 7 RECEPTOR-BINDING CHOLINERGIC AGONISTS
    • 使用ALPHA 7受体结合胆碱酯酸激酶的抑制作用
    • WO2004052365A2
    • 2004-06-24
    • PCT/US2003/038708
    • 2003-12-05
    • NORTH SHORE-LONG ISLAND JEWISH RESEARCH INSTITUTETRACEY, Kevin, J.WANG, Hong
    • TRACEY, Kevin, J.WANG, Hong
    • A61K31/444
    • G01N33/6863A61K31/00A61K31/439A61K31/444A61K31/46G01N33/9406G01N2333/525G01N2333/54Y02A50/385Y02A50/411
    • Methods of inhibiting release of a proinflammatory cytokine from a macrophage are provided. The methods comprise treating the macrophage with a cholinergic agonist in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from the macrophage, wherein the cholinergic agonist is selective for an α7 nicotinic receptor. Methods for inhibiting an inflammatory cytokine cascade in a patient are also provided. The methods comprise treating the patient with a cholinergic agonist in an amount sufficient to inhibit the inflammatory cytokine cascade, wherein the cholinergic agonist is selective for an α7 nicotinic receptor. Methods for determining whether a compound is a cholinergic agonist reactive with an α7 nicotinic receptor are also provided. The methods comprise determining whether the compound inhibits release of a proinflammatory cytokine from a mammalian cell. Additionally, methods for determining whether a compound is a cholinergic antagonist reactive with an α7 nicotinic receptor are provided. These methods comprise determining whether the compound reduces the ability of a cholinergic agonist to inhibit the release of a proinflammatory cytokine from a mammalian cell. Oligonucleotides or mimetics capable of inhibiting attenuation of lipopolysaccharide-induced TNF release from a mammalian macrophage upon exposure of the macrophage to a cholinergic agonist are also provided. The oligonucleotides or mimetics consist essentially of a sequence greater than 5 nucleotides long that is complementary to an mRNA of an α7 receptor. Additionally, methods of inhibiting attenuation of TNF release from a mammalian macrophage upon exposure of the macrophage to a cholinergic agonist are provided. These methods comprise treating the macrophage with the above-described oligonucleotide or mimetic.
    • 提供了抑制促炎细胞因子从巨噬细胞释放的方法。 所述方法包括用足以减少从巨噬细胞释放的促炎细胞因子的量的胆碱能激动剂处理巨噬细胞,其中胆碱能激动剂对α7烟碱受体具有选择性。 还提供了用于抑制患者中炎性细胞因子级联的方法。 所述方法包括用足以抑制炎性细胞因子级联的量的胆碱能激动剂治疗患者,其中胆碱能激动剂对α7烟碱受体具有选择性。 还提供了确定化合物是否是与α7烟碱受体反应的胆碱能激动剂的方法。 所述方法包括确定化合物是否抑制来自哺乳动物细胞的促炎细胞因子的释放。 另外,提供了确定化合物是否是与α7烟碱受体反应的胆碱能拮抗剂的方法。 这些方法包括确定该化合物是否降低胆碱能激动剂抑制促炎细胞因子从哺乳动物细胞释放的能力。 还提供了能够抑制巨噬细胞暴露于胆碱能激动剂时从哺乳动物巨噬细胞中减少脂多糖诱导的TNF释放的寡核苷酸或模拟物。 寡核苷酸或模拟物基本上由与α7受体的mRNA互补的大于5个核苷酸长的序列组成。 此外,提供了在将巨噬细胞暴露于胆碱能激动剂时抑制TNF释放从哺乳动物巨噬细胞的减少的方法。 这些方法包括用上述寡核苷酸或模拟物处理巨噬细胞。
    • 4. 发明申请
    • HANDOVER METHOD SUPPORTING TERMINAL MOBILITY
    • 支持终端移动的切换方法
    • WO2011142567A2
    • 2011-11-17
    • PCT/KR2011/003438
    • 2011-05-09
    • SAMSUNG ELECTRONICS CO., LTD.LIANG, HuaruiWANG, HongXU, Lixiang
    • LIANG, HuaruiWANG, HongXU, Lixiang
    • H04W36/32H04W36/14
    • H04W76/064H04W8/082H04W28/04H04W28/06H04W36/08H04W48/02H04W72/00H04W76/19H04W76/34
    • A handover method for supporting terminal mobility is provided. Before a target core network node updates bearer information according to a target base station to which a User Equipment (UE) performs the handover, an access control determination procedure is added. According to the access control determination information provided by the target base station, if it is determined that the bearer supporting a Selected Internet Protocol (IP) Traffic Offload (SIPTO) or Local IP Access (LIPA) service is permitted to perform the handover, the target core network node updates the bearer information. If it is determined that the bearer supporting the SIPTO or LIPA service is not allowed to perform the handover, the handover failure is notified with respect to the bearer not allowed to perform the handover, and the bearer information is not updated, thus the wasted signaling resource and wireless resource are reduced. Alternatively, during the handover to the target network by the UE or after the handover to the target network, the bearer release or deactivation is performed for the bearer not allowed to perform the handover, so that the UE can re-initiate the bearer establishment process with respect to the bearer not allowed to perform the handover, thus an optimized bearer is established and the Quality of Service (QoS) is ensured.
    • 提供了一种用于支持终端移动性的切换方法。 在目标核心网节点根据用户设备(UE)执行切换的目标基站更新承载信息之前,添加访问控制确定过程。 根据由目标基站提供的访问控制确定信息,如果确定支持选定的因特网协议(IP)流量卸载(SIPTO)或本地IP访问(LIPA))服务的承载被执行切换,则 目标核心网节点更新承载信息。 如果确定支持SIPTO或LIPA业务的承载不允许执行切换,就不允许执行切换的承载通知切换失败,并且不更新承载信息,从而浪费信令 资源和无线资源减少。 或者,在UE切换到目标网络期间或在切换到目标网络之后,对不允许执行切换的承载执行承载释放或去激活,使得UE可以重新发起承载建立过程 对于不允许执行切换的承载,由此建立优化的承载并且确保服务质量(QoS)。